Compare LQDA & RXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LQDA | RXO |
|---|---|---|
| Founded | 2004 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.5B |
| IPO Year | 2020 | 2022 |
| Metric | LQDA | RXO |
|---|---|---|
| Price | $77.99 | $29.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 13 |
| Target Price | ★ $41.00 | $16.33 |
| AVG Volume (30 Days) | ★ 2.1M | 1.5M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.81 | ★ 72.81 |
| EPS | ★ 0.52 | N/A |
| Revenue | $158,320,000.00 | ★ $5,742,000,000.00 |
| Revenue This Year | $278.87 | $0.49 |
| Revenue Next Year | $57.13 | $6.90 |
| P/E Ratio | $148.19 | ★ N/A |
| Revenue Growth | ★ 1031.18 | 26.20 |
| 52 Week Low | $16.51 | $10.43 |
| 52 Week High | $82.96 | $29.86 |
| Indicator | LQDA | RXO |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 63.36 |
| Support Level | $70.28 | $25.28 |
| Resistance Level | $82.96 | $29.24 |
| Average True Range (ATR) | 4.58 | 1.42 |
| MACD | -0.89 | 0.12 |
| Stochastic Oscillator | 61.43 | 85.15 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
RXO Inc is a brokered transportation platform defined by technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.